Standard care or no added treatment
Standard care or no added treatment
STANDARD_CARE
Related
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Type 2 diabetes (adults) | HbA1c change | weeks 20 to 36 (target week 26) | Placebo | MD -0.84 (-1.59 to -0.08) | 0.48 |
| Type 2 diabetes (adults) | HbA1c change | weeks 20 to 36 (target week 26) | Placebo | MD -0.72 (-1.49 to 0.05) | 0.43 |
| Type 2 diabetes (adults) | HbA1c change | weeks 36 to 64 (target week 52) | Placebo | MD -0.45 (-1.28 to 0.45) | 0.35 |
| Type 2 diabetes (adults) | HbA1c change | weeks 20 to 36 (target week 26) | Placebo | MD -0.54 (-1.26 to 0.56) | 0.25 |
| Type 2 diabetes (adults) | HbA1c change | weeks 20 to 36 (target week 26) | Placebo | MD -0.55 (-1.34 to 0.48) | 0.27 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 20 to 36 (target week 26) | Placebo | MD 1.31 (-1.27 to 3.84) | 0.26 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 20 to 36 (target week 26) | Placebo | MD 1.60 (-1.46 to 4.62) | 0.30 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 36 to 64 (target week 52) | Placebo | MD -3.49 (-7.58 to 1.14) | 0.71 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 20 to 36 (target week 26) | Placebo | MD 0.52 (-4.79 to 7.79) | 0.24 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 20 to 36 (target week 26) | Placebo | MD 0.51 (-4.79 to 7.93) | 0.28 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 0.14 (0.01 to 2.51) | 0.66 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 0.13 (0.01 to 1.60) | 0.64 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 3.02 (0.98 to 9.52) | 0.41 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 2.13 (0.79 to 5.73) | 0.57 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 3.69 (1.40 to 9.15) | 0.19 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 3.14 (1.11 to 8.55) | 0.23 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 0.28 (0.02 to 2.06) | 0.76 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 0.26 (0.02 to 2.11) | 0.79 |
| Type 2 diabetes (adults) | Systolic blood pressure change | weeks 20 to 36 (target week 26) | Placebo | MD 2.51 (-1.70 to 6.78) | 0.10 |
| Type 2 diabetes (adults) | Systolic blood pressure change | weeks 20 to 36 (target week 26) | Placebo | MD 2.61 (-1.89 to 6.97) | 0.12 |
| Type 2 diabetes (adults) | Systolic blood pressure change | weeks 36 to 64 (target week 52) | Placebo | MD 8.72 (2.30 to 15.33) | 0.06 |
| Type 2 diabetes (adults) | Systolic blood pressure change | weeks 36 to 64 (target week 52) | Placebo | MD 6.12 (0.11 to 13.30) | 0.06 |
| Type 2 diabetes (adults) | Systolic blood pressure change | weeks 36 to 64 (target week 52) | Placebo | MD -1.95 (-15.30 to 11.91) | 0.50 |
| Type 2 diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 0.30 (0.02 to 3.77) | 0.74 |
| Type 2 diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 0.92 (0.52 to 1.59) | 0.55 |
| Type 2 diabetes (adults) | Discontinuation due to adverse events | longest follow-up | Placebo | HR 0.62 (0.01 to 50.85) | 0.64 |
| Type 2 diabetes (adults) | Discontinuation due to adverse events | longest follow-up | Placebo | HR 0.62 (0.01 to 60.54) | 0.62 |
| Type 2 diabetes (adults) | Nausea | longest follow-up | Placebo | HR 0.61 (0.13 to 2.19) | 0.83 |
| Type 2 diabetes (adults) | Nausea | longest follow-up | Placebo | HR 0.43 (0.10 to 1.45) | 0.76 |
| Type 2 diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 0.27 (0.03 to 1.60) | 0.90 |
| Type 2 diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 0.28 (0.03 to 1.60) | 0.86 |
| Type 2 diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 1.06 (0.34 to 3.01) | 0.66 |
| Type 2 diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 1.04 (0.32 to 3.08) | 0.61 |
| Type 2 diabetes (adults) | Constipation | longest follow-up | Placebo | HR 0.20 (0.04 to 0.73) | 0.91 |
| Type 2 diabetes (adults) | Constipation | longest follow-up | Placebo | HR 0.21 (0.04 to 0.80) | 0.88 |
| Type 2 diabetes (adults) | Discontinuation due to gastrointestinal adverse events | longest follow-up | Placebo | HR 0.58 (0.01 to 31.91) | 0.64 |
| Type 2 diabetes (adults) | Discontinuation due to gastrointestinal adverse events | longest follow-up | Placebo | HR 0.56 (0.01 to 27.88) | 0.59 |
| Type 2 diabetes (adults) | Acute pancreatitis | longest follow-up | Placebo | HR 0.76 (0.04 to 13.30) | 0.50 |
| Type 2 diabetes (adults) | Acute pancreatitis | longest follow-up | Placebo | HR 0.74 (0.04 to 13.23) | 0.43 |
| Type 2 diabetes (adults) | Pancreatic cancer | longest follow-up | Placebo | HR 0.80 (0.05 to 14.50) | 0.50 |
| Type 2 diabetes (adults) | Pancreatic cancer | longest follow-up | Placebo | HR 0.80 (0.05 to 12.43) | 0.50 |
| Type 2 diabetes (adults) | Acute kidney injury | longest follow-up | Placebo | HR 0.51 (0.01 to 40.24) | 0.54 |
| Overweight or obesity without diabetes (adults) | Systolic blood pressure change | weeks 40 to 104 (target week 68) | Placebo | MD -3.48 (-10.36 to 3.14) | 0.46 |
| Overweight or obesity without diabetes (adults) | Systolic blood pressure change | weeks 40 to 104 (target week 68) | Placebo | MD -4.20 (-9.90 to 1.07) | 0.57 |
| Overweight or obesity without diabetes (adults) | Percent body weight change | weeks 40 to 104 (target week 68) | Placebo | MD 0.07 (-3.80 to 4.17) | 0.05 |
| Overweight or obesity without diabetes (adults) | Percent body weight change | weeks 40 to 104 (target week 68) | Placebo | MD 1.73 (-2.84 to 5.98) | 0.04 |
| Overweight or obesity without diabetes (adults) | Percent body weight change | weeks 20 to 40 (target week 26) | Placebo | MD -0.66 (-9.85 to 8.19) | 0.13 |
| Overweight or obesity without diabetes (adults) | Percent body weight change | weeks 20 to 40 (target week 26) | Placebo | MD -0.79 (-9.49 to 8.42) | 0.18 |
| Overweight or obesity without diabetes (adults) | Weight loss of 5 percent or more | weeks 20 to 40 (target week 26) | Placebo | OR 0.87 (0.14 to 5.31) | 0.07 |
| Overweight or obesity without diabetes (adults) | Weight loss of 5 percent or more | weeks 20 to 40 (target week 26) | Placebo | OR 0.87 (0.21 to 3.39) | 0.09 |
| Overweight or obesity without diabetes (adults) | Weight loss of 10 percent or more | weeks 40 to 104 (target week 68) | Placebo | OR 0.29 (0.07 to 1.31) | 0.01 |
| Overweight or obesity without diabetes (adults) | Weight loss of 10 percent or more | weeks 40 to 104 (target week 68) | Placebo | OR 0.28 (0.05 to 1.64) | 0.01 |
| Overweight or obesity without diabetes (adults) | Weight loss of 10 percent or more | weeks 20 to 40 (target week 26) | Placebo | OR 2.34 (0.28 to 13.63) | 0.20 |
| Overweight or obesity without diabetes (adults) | Weight loss of 10 percent or more | weeks 20 to 40 (target week 26) | Placebo | OR 2.41 (0.35 to 12.64) | 0.24 |
| Overweight or obesity without diabetes (adults) | Weight loss of 15 percent or more | weeks 40 to 104 (target week 68) | Placebo | OR 0.30 (0.08 to 1.24) | 0.01 |
| Overweight or obesity without diabetes (adults) | Weight loss of 15 percent or more | weeks 40 to 104 (target week 68) | Placebo | OR 0.30 (0.07 to 1.34) | 0.01 |
| Overweight or obesity without diabetes (adults) | SF-36 physical component summary change | weeks 20 to 130 (target week 52) | Placebo | MD -0.50 (-8.73 to 7.33) | 0.26 |
| Overweight or obesity without diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 0.74 (0.28 to 1.83) | 0.65 |
| Overweight or obesity without diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 1.26 (0.66 to 2.42) | 0.52 |
| Overweight or obesity without diabetes (adults) | Discontinuation due to adverse events | longest follow-up | Placebo | HR 0.37 (0.02 to 7.15) | 0.77 |
| Overweight or obesity without diabetes (adults) | Discontinuation due to adverse events | longest follow-up | Placebo | HR 1.96 (0.63 to 5.79) | 0.55 |
| Overweight or obesity without diabetes (adults) | Nausea | longest follow-up | Placebo | HR 0.05 (0.01 to 0.21) | 0.99 |
| Overweight or obesity without diabetes (adults) | Nausea | longest follow-up | Placebo | HR 0.19 (0.08 to 0.36) | 0.97 |
| Overweight or obesity without diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 0.16 (0.02 to 0.70) | 0.98 |
| Overweight or obesity without diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 0.37 (0.11 to 1.01) | 0.97 |
| Overweight or obesity without diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 0.06 (0.01 to 0.22) | 0.99 |
| Overweight or obesity without diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 0.21 (0.09 to 0.48) | 0.95 |
| Overweight or obesity without diabetes (adults) | Constipation | longest follow-up | Placebo | HR 0.19 (0.05 to 0.55) | 0.94 |
| Overweight or obesity without diabetes (adults) | Constipation | longest follow-up | Placebo | HR 0.23 (0.09 to 0.51) | 0.94 |
| Overweight or obesity without diabetes (adults) | Discontinuation due to gastrointestinal adverse events | longest follow-up | Placebo | HR 0.25 (0.01 to 4.75) | 0.84 |
| Children and adolescents with type 2 diabetes | Serious adverse events | longest follow-up | Placebo | HR 0.61 (0.01 to 51.55) | 0.59 |
| Children and adolescents with type 2 diabetes | Nausea | longest follow-up | Placebo | HR 1.36 (0.07 to 22.24) | 0.51 |
| Children and adolescents with type 2 diabetes | Vomiting | longest follow-up | Placebo | HR 0.15 (0.00 to 2.94) | 0.94 |
| Children and adolescents with type 2 diabetes | Diarrhea | longest follow-up | Placebo | HR 1.10 (0.10 to 10.89) | 0.58 |
| Type 1 diabetes | HbA1c change | weeks 12 to 40 (target week 26) | Placebo | MD 0.12 (-0.91 to 1.16) | 0.27 |
| Type 1 diabetes | HbA1c change | weeks 12 to 40 (target week 26) | Placebo | MD 0.11 (-1.03 to 1.25) | 0.24 |
| Type 1 diabetes | Total daily insulin dose change | weeks 12 to 40 (target week 26) | Placebo | MD 0.12 (-0.79 to 1.06) | 0.34 |
| Type 1 diabetes | Total daily insulin dose change | weeks 12 to 40 (target week 26) | Placebo | MD 0.12 (-0.82 to 1.05) | 0.35 |
Trials
- S0030901 weeks
- S00306819 randomized · 36 weeks
- S00303250 randomized · 34.76 weeks
- S0030230.43 weeks
- S00307060 randomized · 2 weeks
- TOGETHER-PsAEfficacy and Safety of Ixekizumab or Ixekizumab Concomitantly Administered With Tirzepatide in Adult Participants With Active Psoriatic Arthritis and Obesity or Overweight: A Phase 3b, Randomized, Multicenter, Open-Label Study (TOGETHER-PsA)2024 · 279 randomized · 52 weeks
- TOGETHER-PsOEfficacy and Safety of Ixekizumab or Ixekizumab Concomitantly Administered With Tirzepatide in Adult Participants With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight: A Phase 3b, Randomized, Multicenter, Open-Label Study (TOGETHER-PsO)2024 · 281 randomized · 52 weeks
- S0034222023 · 64 randomized · 12 weeks
- NCT05786521The Effect of GLP1 Receptor Agonists on Physical Function, Body Composition, and Biomarkers of Aging in Older Overweight/Obese Adults With Insulin Resistance2023 · 20 randomized · 20 weeks
- ENDISImpact of Additional Treatment With Empagliflozin or Semaglutide on Endothelial Function and Other Clinical Parameters and Biomarkers in T1DM Patients2021 · 91 randomized · 12 weeks
- NCT04969627Effects of GLP-1 Analogue Combined With Metformin and Metformin on Gonadal and Metabolic Profiles in Chinese Overweight/Obese PCOS Patients With Hyperandrogenemia.2021 · 60 randomized · 12 weeks
- NCT04876027Dulaglutide and Calorie Restrict Diet (CRD) in Overweight/Obese Patients With Polycystic Ovary Syndrome2021 · 68 randomized · 26.07 weeks
- S0031002019 · 90 randomized · 13.04 weeks
- NCT04029272Study on the Effect of Metformin vs Metformin Combined With GLP-1 RA (Exenatide) on Overweight/Obese Patients With Polycystic Ovary Syndrome (PCOS)2019 · 50 randomized · 12 weeks
- NCT03596450Long Term Comparative Effectiveness of Once Weekly Semaglutide Versus Standard of Care in a Real World Adult US Population With Type 2 Diabetes - a Randomized Pragmatic Clinical Trial2018 · 1,278 randomized · 104.36 weeks
- D-LIFTEffect of Dulaglutide on Liver Fat in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial2018 · 64 randomized · 24 weeks
- NCT03824002Arterial Stiffness and Endothelial Function Indexes, Relationships With Clinical and Laboratory Variables in a Group of Diabetic Patients in Treatment With Dulaglutide: a Case-control Study2017 · 39.11 weeks
- NCT02960659Therapeutic Targets in African-American Youth With Type 2 Diabetes2017 · 24 randomized · 12 weeks
- STRIVEEFFECTIVENESS AND COST OF INTEGRATING A PROTOCOL WITH USE OF LIRAGLUTIDE 3.0 MG INTO AN OBESITY SERVICE: (STRIVE Study)2017 · 392 randomized · 104 weeks
- RebuildEffects on Re-endothelialisation With Bydureon Treatment Add on to Insulin Versus Insulin Alone, Both in Combination With Metformin in Type 2 Diabetic Subjects2015 · 38 randomized · 12 weeks
- PREVAILPreserving Beta-cell Function in Type 2 Diabetes With Exenatide and Insulin (PREVAIL)2014 · 103 randomized · 8 weeks
- ELEGANTThe Effect of Liraglutide on Insulin-associated wEight GAiN in Patients With Type 2 Diabetes Mellitus (ELEGANT Trial)2012 · 50 randomized · 26 weeks
- NCT01776788Effect of Short-Term Intensive Insulin Sequential Exenatide Therapy on β-cell Function and Glycemic Remission Rate in Newly Diagnosed Type 2 Diabetic Patients2012 · 130 randomized · 12 weeks
- S0030752011 · 52 randomized · 52 weeks
- S0030792010 · 36 randomized · 5 weeks
- NCT00971659Acute Effect of a GLP-1-Analogue (Exenatide) and of a DPP-4-Inhibitor (Sitagliptin) in Subjects With Type 2 Diabetes Treated With Insulin Glargine Once Daily2008 · 48 randomized · 4 weeks
- NCT01432405Effect of Exenatide Treatment on Hepatic Fat Content and Plasma Adipocytokine Levels in Patients With Type 2 Diabetes Mellitus2007 · 24 randomized · 52.14 weeks